Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

NCT05340374 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer
mCRPC

Interventions

DRUG: Cabazitaxel
DRUG: 177Lu-PSMA-617

Sponsor

Peter MacCallum Cancer Centre, Australia